
    
      This will be a single-site, single-dose, randomized, open-label, two-treatment, two-sequence,
      four-period replicated crossover study in healthy adult subjects. The study will comprise a
      screening period, four treatment periods with a 7-day washout between dosing in each period,
      and a safety follow-up visit.
    
  